Aclaris Therapeutics (ACRS) Total Non-Current Liabilities (2016 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Total Non-Current Liabilities of $53.7 million for Q1 2026, up 7.91% year-over-year from $49.7 million in Q1 2025, and up 15.69% quarter-over-quarter from $46.4 million in Q4 2025.
Aclaris Therapeutics (ACRS) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Aclaris Therapeutics' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $53.7 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 7.91% year-over-year to $53.7 million; the TTM figure through Mar 2026 stood at $53.7 million (up 7.91% YoY), while the FY2025 annual figure was $46.4 million, down 23.13% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $53.7 million, up from $46.4 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $60.3 million in Q4 2024, with the low at $18.0 million in Q2 2024.
- The 5-year median for Total Non-Current Liabilities is $37.2 million (2023), against an average of $37.0 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities slumped 64.1% in 2022, then jumped 207.81% in 2025.
- Aclaris Therapeutics' Total Non-Current Liabilities stood at $23.9 million in 2022, then jumped by 55.61% to $37.2 million in 2023, then soared by 62.4% to $60.3 million in 2024, then slipped by 23.13% to $46.4 million in 2025, then gained by 15.69% to $53.7 million in 2026.
- Business Quant data shows ACRS's Total Non-Current Liabilities at $53.7 million in Q1 2026, $46.4 million in Q4 2025, and $53.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 43.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.81 Mn |
| Mar 31, 2026 | 53.66 Mn |
| Dec 31, 2025 | 46.38 Mn |
| Sep 30, 2025 | 53.72 Mn |
| Jun 30, 2025 | 55.56 Mn |
| Mar 31, 2025 | 49.72 Mn |
| Dec 31, 2024 | 60.33 Mn |
| Sep 30, 2024 | 42.24 Mn |
| Jun 30, 2024 | 18.05 Mn |
| Mar 31, 2024 | 23.05 Mn |
| Dec 31, 2023 | 37.15 Mn |
| Sep 30, 2023 | 60.19 Mn |
| Jun 30, 2023 | 25.10 Mn |
| Mar 31, 2023 | 20.60 Mn |
| Dec 31, 2022 | 23.88 Mn |
| Sep 30, 2022 | 21.79 Mn |
| Jun 30, 2022 | 18.42 Mn |
| Mar 31, 2022 | 19.13 Mn |
| Dec 31, 2021 | 25.47 Mn |
| Sep 30, 2021 | 20.71 Mn |